Founder & CEO
Founder & Chief Executive Officer of Govin Capital, a Singapore-based company with interests in Investment, Education & Social entrepreneurship. Anand has 18 years of active investment management experience and is a veteran healthcare investor.
Founder & Chief Executive Officer of GOVIN Holdings, a Singapore-based company with interests in Investment Banking, Education & Social entrepreneurship. Anand has 15 years of active investment management experience and is a veteran healthcare investor.
Prior to GOVIN, Anand served as the Senior Vice President & Head of the Investment, Spin-Off Management Division at ETPL, A*STAR, Government of Singapore for 3 years. At ETPL, he with his team actively managed a portfolio of 40 companies that are in the fields of Infocomm, Engineering, Aerospace, Medtech & Biotech. In additon, he actively organized Technopreneurship & Investor workshops for researcher and scientific community at A*STAR.
Prior to joining ETPL, Anand was at Temasek Holdings, Singapore for 8 years. At Temasek, Anand was active across the value-chain of investments in the healthcare arena - from deal sourcing, to conducting on-site due-diligence, negotiating term-sheets, serving on the boards of companies for strategic development and planning exit strategies. Some of the investments that he executed include - Merlion Pharma (Singapore), Biosensors International (Singapore), TauRx (Singapore), Quintiles (USA), Aptuit (USA), IdunPharma (USA; acquired by Pfizer), Agilix (USA; acquired by Perkin), Vical (USA), Intercell (Austria), Arpida (Basel), Elbion (Germany), BioVex (UK), Renovo (Manchester), Dr Reddy Labs (India), Medreich (India), etc.
Anand serves as Board member of UAL Biotech (Singapore), and an Advisory Board member of the Singapore-MIT Alliance for Research & Technology (SMART). He is also an invitee Judge for Lee Kuan Yew Global Business Plan Competition organized by Singapore Management University, Start-Up Singapore organized by The National University of Singapore & Start-Up Chile. He is a regular panel speaker in various investor conferences globally.
Anand is a Life Member of YMCA, Singapore and also participates in social service for the underprivileged community in Asia through his foundation, Heart2Heart Foundation ( www.govinfoundation.org ).
Anand has earned a Master's degree in Business Administration from California State University, East Bay, USA; Master of Science degree from National University of Singapore, Singapore and Master of Science degree in Molecular Biology & Biotechnology from G B Pant University, India.
Govin Capital, a Singapore-based investment company announced the appointment of Mr Goran S Malm to its Board of Directors. Govin Capital was incorporated in 2014 by leading healthcare investor, Mr Anand Govindaluri with the aim of investing in companies that serve its 3 main themes, mainly companies that are technological innovative, serve the emerging middle-class and have a societal impact.
Göran S. Malm holds important Board Assignments in Asia and globally. He is currently on the Board of Dornier MedTech GmbH Singapore, UFI Italy, Chairman of Boathouse Ltd – a Cayman Island investment Company, Board member of Elife Japan and Chairman of Smartpay Jieyin China.
Between 2000-2005, Mr Malm served as Board Member of Keppel T&T, Singapore and CVC Capital Partners Advisory Board, Hong Kong and during 2004 – 2007 as Board Member of CellMark AB and Invest in Sweden Agency and 2003-2010 as Board Member of Micronic Laser Systems Sweden. Between 2010 and 2011, Malm also served in Domsjö Group AB Sweden.
Between 2005 and 2012 Mr Malm served as Chairman of North Asia Strategic Holding – a HK listed investment holding company and between 2007 and 2012 as Board member of Envac AB of Sweden.
Furthermore Mr Malm served 9 years (2001-2010) as Independent Director of Samsung Electronics Co Ltd, Seoul Korea. Prior to 2001, Mr Malm was President Asia Pacific and Senior Vice President for Dell Computer Corporation, where he was responsible for Dell’s business operations in the region with a size of US$3billion in revenue and 3,500 employees. From 1997 to 1999, Mr Malm was Senior Vice President of General Electric (GE) Company and President of General Electric Asia Pacific with the base in Hong Kong, where he was regionally responsible for the company’s 11 business units totalling US$10billion in Revenues with 40,000 employees.
Between 1992 and 1997 Mr Malm held position of President and CEO of GE Medical Systems Asia and Vice President of General Electric (GE) Company. In this position he developed the organization into a fully integrated region-wide business, growing revenues to US$1billion and earnings to US$100 mill with 4,000 employees. Mr Malm is a 20-year veteran of the major Swedish conglomerate AB SKF, where he with Gothenburg, Sweden as a base held several positions in finance, marketing, regional management, business development and services and ended up as Deputy Group Managing Director in 1990.
D A Prasanna is appointed on the Board of Startup Accelerator India, a member of Govin Capital, Singapore.
As Founder & Chairman of Ecron Acunova CRO, Prasanna has shaped the vision to help clients bring affordable and high quality drugs, devices and therapies to market. He has worked in global CEO positions in healthcare business of GE-India and GE-Japan. He was Vice Chairman of Wipro, a leading Indian technology service company. He has served as an Independent Director on the Boards of Life Science companies like Shasun Pharma, Take Solutions, For Ways Healthcare PLC, etc. Served as Chairman of GE-BEL, Ecron Acunova GmbH, as Director on GE Yokogawa Japan, GE-Samsung Korea, Manipal Gp, Manipal Hospitals, Manipal University and is reputed for contributing to strategies & building new stakeholders. He has served as Chairman of Wipro Fluid Power in infrastructure industry. He served on Public Policy advocacy organizations like Center For Policy Research for over a decade.
Prasanna is a pioneer in creating markets for high-technology medical equipment, delivering clinical excellence at low per patient fees, through frugal innovation. This background enabled him to found a CRO, which became the India's leading clinical CRO. He laid the foundation for cell therapy research leading to an allogenic stem cell company. This passion led to EA specializing in cell therapy studies. He is an early stage investor in this space. He has mentored startups and portfolio companies of international funds. He is strategic Advisor to InnAccel, a leading med-tech accelerator.
He is Chairman of Association of CROs (ACRO India). He is member of: Vision Group on Biotechnology, Karnataka; Biotechnology National Council and Pharmaceutical National Council of CII (Confederation of Indian Industry). He is a Trustee on Shriram Ownership Trust, which shapes direction of Shriram group. He is considered a thought leader in pharma, biotech, Healthcare, Education and IT sectors. He has mentored CEO and woman with potential to serve on Board of Directors
He has run effectively as MD or CEO or Executive Chairman large companies in Wipro, GE, Manipal Group before becoming an entrepreneur.
He is an alumnus of IIM Ahmedabad & GE Business Leadership Program at Crotonville.
He is married to Rajani, an Art Historian and they live in Bangalore India.
Dr. Makarand Jawadekar was formerly a Director, Portfolio Management & Analytics, Pfizer, Inc. at Groton-New London, CT. In the recent past, he was responsible for Benchmarking R & D Portfolio for Pfizer, working with Benchmarking Forums (CMR/KMR), Drug Delivery Technology Assessment function involving external 'Drug Delivery' technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies for Pfizer Global R & D. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota.
He has continuous twenty-eight plus years of experience with Pfizer Inc. (Includes R & D and Worldwide Pharmaceutical organization). R & D areas include heading Solids R & D, Drug Product formulation/ Dosage Form/ Drug Delivery research & development, Clinical Trials Supply Manufacturing and Packaging, Scale-up and Technology Transfer as well as Pharmacy (CMC) areas. He managed several functions/groups within Pharmaceutical R & D for many years. In the recent past, he had been also been engaged in creating new alliances, JVs, partnerships and M & A of companies with Pharmaceutical manufacturing, R & D activities with external partners/service providers. He was presented with the "M.L. Khorana Memorial Lecture of the Year Award" at the Indian Pharmaceutical Congress held in New Delhi, India, in December 2001 for his Presentation on 'Advances in Drug Development and Delivery Systems with a Focus on Protection of Intellectual Property Rights'. He has presented at many professional meetings and has participated in various Panel Discussions/ Round Tables. He was one of the invited guests for a 'Leadership Summit' held by the President of India, Dr. Abdul Kalam during 2003. He was also one of the invitees to join President George W. Bush's trade delegation to India in March 2006. During December 2007, Mak accompanied Dr. John LaMattina (former Pfizer President) to India on his official trip to India, where President of India, Mrs. PratibhaPatil invited both of them to the President’s Palace (RashtrapatiBhavan) in New Delhi. He also recently accompanied Pfizer R & D President Dr. Martin Mackay during Feb 2009 to India for participating in Bio Asia 2009.He served as a Vice president of Asia CRG at Pfizer Inc. He recently (Feb 2011) received an honorary Doctorate from DYP Mumbai University.
He also serves on the prestigious global "Judging Panel"/ Executive Review Board instituted by IBC/ InformaPharma Group for their Annual Pharmaceutical Annual Achievement Awards, as well as European Outsourcing Awards by Via-Media Ltd.
He currently serves as a member on the Editorial boards for ‘Bio/Pharmaceutical Outsourcing Report’ as well as for "Contract Pharma" a monthly publication. He also is on the Editorial Advisory Board for monthly publication namely, “Pharmaceutical Technology Europe".